afamelanotide in Stroke (AIS) - Positive Preliminary Results
Filed with ASX · · 3 pages · English
First use of afamelanotide in arterial ischaemic stroke (AIS) patients Drug well tolerated Five of six patients showed improved neurological functions (NIHSS¹ scores) Final results on day 42 of the trial to follow. CLINUVEL today released positive preliminary results from its pilot study (CUV801) in arterial ischaemic stroke (AIS), evaluating afamelanotide in six adult patients. The trial focused
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL Reports December Half Year Operating Results
- Appendix 4D Half Year Report
- Response to ASX Price Query
- CLINUVEL Delivers Record Revenues and Profit
- Appendix 4E and Preliminary Financial Report
Later from Clinuvel Pharmaceuticals
- ACTH Manufacturing Update
- Positive Final Results in Stroke Study CUV801
- Appendix 4E and Annual Report 2022
- S&P DJI Announces September 2022 Quarterly Rebalance
- Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals